Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3GNRHRMPLPDE3APDE3BPDE4APDE4BPDE4CPDE4DPPARASLC5A2
The experimentally established mechanism targets of Choline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.60 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.44 |
| ▸ | HTR1A | P08908 | 2/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GALR3 | O60755 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | CPT2 | P23786 | 1/20 | 0.37 |
| ▸ | CPT1A | P50416 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Choline SCHEMBL3458979 | 0.97 | LMNA (0.57) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Choline SCHEMBL3458973 | 0.97 | CYP3A4 (0.65) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Choline SCHEMBL20358854 | 0.90 | LMNA (0.55) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Choline SCHEMBL23355962 | 0.89 | LMNA (0.67) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Choline SCHEMBL119824 | 0.89 | LMNA (0.67) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Choline SCHEMBL15993952 | 0.88 | CYP3A4 (0.59) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Choline SCHEMBL2222247 | 0.86 | LMNA (0.63) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Choline SCHEMBL516453 | 0.86 | CYP3A4 (0.72) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Choline SCHEMBL316506 | 0.86 | LMNA (0.63) | LMNAMEN1KMT2ACYP3A4SLC5A7 | |
| Choline SCHEMBL15993853 | 0.86 | LMNA (0.63) | LMNAMEN1KMT2ACYP3A4SLC5A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117039207-B | Battery, iodine electrode material and preparation method of electrolyte | 广东工业大学 | 2024-07-30 | — | — | CN | claimed |
| CN-117039207-A | Battery, iodine electrode material and preparation method of electrolyte | 广东工业大学 | 2023-11-10 | — | — | CN | claimed |
| US-20260085166-A1 | BACTERIAL CELLULOSE GELS, PROCESS FOR PRODUCING AND METHODS FOR USE | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2026-03-26 | — | — | US | disclosed |
| US-12486376-B2 | Bacterial cellulose gels, process for producing and methods for use | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250122350-A1 | CELLULOSE-ENABLED ORIENTATIONALLY ORDERED FLEXIBLE GELS | UNIV COLORADO REGENTS (US) | 2025-04-17 | — | — | US | disclosed |
| US-12129353-B2 | Cellulose-enabled orientationally ordered flexible gels | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2024-10-29 | — | — | US | disclosed |
| CN-117039207-B | Battery, iodine electrode material and preparation method of electrolyte | 广东工业大学 | 2024-07-30 | — | — | CN | disclosed |
| US-20240158601-A1 | BACTERIAL CELLULOSE GELS, PROCESS FOR PRODUCING AND METHODS FOR USE | US DEPARTMENT OF ENERGY | 2024-05-16 | — | — | US | disclosed |
| CN-117039207-A | Battery, iodine electrode material and preparation method of electrolyte | 广东工业大学 | 2023-11-10 | — | — | CN | disclosed |
| US-20220168325-A1 | METHODS TO PROMOTE CEREBRAL BLOOD FLOW IN THE BRAIN | THE UNIVERSITY OF VERMONT | 2022-06-02 | — | — | US | disclosed |
| US-11344534-B2 | Cholinergic agonism for the treatment of pancreatic cancer | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2019005874-A1 | CHOLINERGIC AGONISM FOR THE TREATMENT OF PANCREATIC CANCER | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-01-03 | — | — | WO | disclosed |
| US-20180237608-A1 | CELLULOS-ENABLED ORIENTATIONALLY ORDERED FLEXIBLE GELS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2018-08-23 | — | — | US | disclosed |
| WO-2018089204-A2 | COMBINATION THERAPIES FOR TREATING BIPOLAR DISORDER, AND METHODS FOR USING THE SAME | PSYCHNOSTICS, LLC (US) | 2018-05-17 | — | — | WO | disclosed |
| US-6414033-B1 | DETERMINATION PH; BUFFER SOLUTION | GELSUS RESEARCH AND CONSULTING, INC. | 2002-07-02 | — | — | US | disclosed |
| EP-1049424-A4 | A DRUG DOSAGE FORM BASED ON THE TEORELL-MEYER GRADIENT | SCEUSA NICHOLAS A (US) | 2001-11-28 | — | — | EP | disclosed |
| EP-1049424-A1 | A DRUG DOSAGE FORM BASED ON THE TEORELL-MEYER GRADIENT | Sceusa, Nicholas A. (US) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999034751-A1 | A DRUG DOSAGE FORM BASED ON THE TEORELL-MEYER GRADIENT | SCEUSA NICHOLAS A (US) | 1999-07-15 | — | — | WO | disclosed |
| US-5607691-A | IONTOPHORESIS | AFFYMAX TECHNOLOGIES N.V. (GB) | 1997-03-04 | — | — | US | disclosed |
| CN-85109716-A | Preparation octahydro indoles is (2,3-α) quinolizine-1-base-alkane hydroxy acid acid amides and acid salt thereof and the method that contains their pharmaceutical composition also | — | 1986-10-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344534-B2 | Cholinergic agonism for the treatment of pancreatic cancer | CHRM3, CHRNA1, CHRNA3 | LMNA 4467/4885MEN1 637/4885KMT2A 993/4885 |
| US-20260085166-A1 | BACTERIAL CELLULOSE GELS, PROCESS FOR PRODUCING AND METHODS FOR USE | LRBA, VCL, ILK | LMNA 1307/4885MEN1 3087/4885KMT2A 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.